TTE Improves Clinical Management of Stable Chest Pain

Improving the Clinical Management of Stable Chest Pain Based on Imaging: a Registry of Transthorcic Echocardiography

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07063147

Acronym

TICM-SCP

Enrollment

50000

Registered

2025-07-14

Start date

2025-01-01

Completion date

2040-12-31

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transthorcic Echocardiography, Stable Angina Pectoris, Coronary Artery Disease, Major Adverse Cardiac Events, Invasive Coronary Angiography

Brief summary

The investigator aims to prospectively enroll patients who were referred for transthorcic echocardiography (TTE) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent TTE according to established guidelines and local institutional protocols. This study will determine if TTE-based imaging evaluation can provide more informaton to improve clinical management for SCP, including fewer MACE and better decision-making of downstream investigations and therapeutic interventions.

Interventions

DIAGNOSTIC_TESTTTE

All patients underwent TTE according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* symptomatic patients with SCP suspected of obstructive CAD. * referred for TTE for the assessment of SCP. * ≥18 years of age. * signed informed consent.

Exclusion criteria

* acute coronary syndromes * previous CAD or coronary revascularization * nonsinus rhythm * cardiomyopathy, valvular disease, congenital heart disease or left cardiac insufficiency because of other reasons

Design outcomes

Primary

Measure	Time frame
Major adverse cardiovascular events	10 years

Secondary

Measure	Time frame	Description
Invasive coronary angiography	10 years	Invasive coronary angiography occurred at follow-up after TTE, attributed to TTE results or unplanned.
Medication prescription	10 years	Change for medication prescription of antiplatelet agents, anti-ischemic drugs, lipid-lowering agents, angiotensin-converting enzyme inhibition and so on, attributed to TTE results or unplanned,
Coronary revascularization	10 years	PTCA, PCI or CABG occurred at follow-up after TTE, attributed to TTE results or unplanned.

Countries

China

Contacts

Primary ContactJia Zhou

zhoujiawenzhang@126.com+8615522485560

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026